AbbVie's veliparib wows in a breast cancer study

AbbVie's ($ABBV) PARP inhibitor veliparib improved outcomes for women with triple-negative breast cancer in a new investigator-sponsored study, charting a 52% complete response rate. The study, dubbed I-SPY 2, tested veliparib plus carboplatin and paclitaxel in 71 patients, using Bayesian probability to conclude that the combo is 92% likely to beat out standard therapy. I-SPY 2 is evaluating 7 in-development cancer drugs, including Puma Biotechnologies' ($PBYI) neratinib. Release